- Piramal Pharma Solutions is investing $80 million to expand its Lexington, KY facility, increasing capacity from 104 to over 240 batches annually by 2027.
- The expansion will create more than 40 full-time jobs and add 24,000 square feet of new manufacturing space and equipment.
Piramal Pharma Solutions (PPS), a global contract development and manufacturing organisation (CDMO), has announced an $80 million investment to expand its Lexington, Kentucky facility. This site specialises in sterile compounding, liquid filling, and lyophilisation for injectable drug products and supports Piramal’s ADCelerate programme for antibody-drug conjugate development.
The expansion will add 24,000 square feet to the existing facility, along with new equipment such as a filling line, two commercial-size lyophilisers, a capping machine, and an external vial washer. These additions will increase the site’s production capacity from 104 batches annually to over 240 by the first quarter of 2027. This growth responds to rising demand for sterile injectable drug products.
“This expansion represents a strategic investment in the future of Piramal Pharma Ltd.,” said Nandini Piramal, Chairperson of Piramal Pharma Ltd. The investment aims to position the Lexington site as a key player in the growing injectables market.
Peter DeYoung, CEO of Global Pharma, also highlighted the importance of the project, stating, “This expansion will significantly enhance the capacity and capabilities of our Lexington facility, positioning Piramal Pharma as a comprehensive partner across the entire product life cycle.”
The project will also create over 40 full-time jobs and has already attracted several clients planning to commercialise their products at the expanded site. Kentucky Governor Andy Beshear praised the decision, citing the state’s business-friendly environment as a key factor in Piramal’s choice to reinvest.
Overview of outsourcing trends 
